YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK)
HKD 12.66
(2.76%)
HKD 12.66
(2.76%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.29 Billion CNY | 68.08% |
| 2022 | 3.74 Billion CNY | 309.83% |
| 2021 | 913.78 Million CNY | -61.08% |
| 2020 | 2.34 Billion CNY | -62.27% |
| 2019 | 6.22 Billion CNY | 147.92% |
| 2018 | 2.51 Billion CNY | 56.75% |
| 2017 | 1.6 Billion CNY | 70.11% |
| 2016 | 941.5 Million CNY | 35.88% |
| 2015 | 692.91 Million CNY | 57.16% |
| 2014 | 440.9 Million CNY | 39.34% |
| 2013 | 316.42 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.45 Billion CNY | -20.44% |
| 2023 Q2 | 3.2 Billion CNY | 30.89% |
| 2023 FY | 6.29 Billion CNY | 68.08% |
| 2023 Q4 | 3.08 Billion CNY | -3.85% |
| 2022 Q4 | 2.45 Billion CNY | 89.56% |
| 2022 FY | 3.74 Billion CNY | 309.83% |
| 2022 Q2 | 1.29 Billion CNY | 81.76% |
| 2021 FY | 913.78 Million CNY | -61.08% |
| 2021 Q2 | 202.24 Million CNY | -23.51% |
| 2021 Q4 | 711.54 Million CNY | 251.82% |
| 2020 Q2 | 2.08 Billion CNY | -33.91% |
| 2020 FY | 2.34 Billion CNY | -62.27% |
| 2020 Q4 | 264.4 Million CNY | -87.31% |
| 2019 FY | 6.22 Billion CNY | 147.92% |
| 2019 Q4 | 3.15 Billion CNY | 2.65% |
| 2019 Q2 | 3.07 Billion CNY | 198.75% |
| 2018 FY | 2.51 Billion CNY | 56.75% |
| 2018 Q4 | 1.02 Billion CNY | -30.65% |
| 2018 Q2 | 1.48 Billion CNY | 57.82% |
| 2017 Q2 | 662.25 Million CNY | 71.62% |
| 2017 FY | 1.6 Billion CNY | 70.11% |
| 2017 Q4 | 939.31 Million CNY | 41.84% |
| 2016 Q2 | 555.62 Million CNY | 79.21% |
| 2016 FY | 941.5 Million CNY | 35.88% |
| 2016 Q4 | 385.87 Million CNY | -30.55% |
| 2015 Q2 | 382.86 Million CNY | 92.78% |
| 2015 Q4 | 310.04 Million CNY | -19.02% |
| 2015 FY | 692.91 Million CNY | 57.16% |
| 2014 Q2 | 242.3 Million CNY | 119.83% |
| 2014 Q4 | 198.59 Million CNY | -18.04% |
| 2014 FY | 440.9 Million CNY | 39.34% |
| 2013 FY | 316.42 Million CNY | 0.0% |
| 2013 Q4 | 110.22 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -2328.86% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 40.22% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -10551.096% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -703.003% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -554.805% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -497.757% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -268.847% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -677.967% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -1447.117% |
| SSY Group Limited | 6.46 Billion HKD | 2.606% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -870.765% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -328.845% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 97.672% |